Pharmacoeconomic considerations of treating patients with advanced Parkinson's disease

Bibliography

• Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17(5):427-42
   PubMed Web of Science ®Google Scholar
• Chaudhuri KR, Healy DG, Schapira AH. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 2006;5(3):235-45
   PubMed Web of Science ®Google Scholar
• Stocchi F, Tagliati M, Olanow CW. Treatment of levodopa-induced motor complications. Mov Disord 2008;23(Suppl 3):S599-612
   PubMed Web of Science ®Google Scholar
• Schrag A, Jahanshahi M, Quinn N. What contributes to quality of life in patients with Parkinson's disease? JNNP 2000;69(3):308-12
   PubMed Web of Science ®Google Scholar
• Valldeoriola F. Cost and efficacy of therapies for advanced Parkinson's disease. In: Finkelstein DI, editor. Towards New Therapies for Parkinson's Disease. InTech; 2011
   Google Scholar
• Bach JP, Ziegler U, Deuschl G, Projected numbers of people with movement disorders in the years 2030 and 2050. Mov Disord 2011;26(12):2286-90
   PubMed Web of Science ®Google Scholar
• Dorsey ER, Constantinescu R, Thompson JP, Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2007;68(5):384-6
   PubMed Web of Science ®Google Scholar
• Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-Effectiveness in health and medicine. Oxford University Press; New York: 1996
   Google Scholar
• Eggert KM, Reese JP, Oertel WH, Dodel R. Cost effectiveness of pharmacotherapies in early Parkinson's disease. CNS Drugs 2008;22(10):841-60
   PubMed Web of Science ®Google Scholar
• LePen C, Wait S, Moutard-Martin F, Cost of illness and disease severity in a cohort of French patients with Parkinson's disease. PharmacoEconomics 1999;16:59-69
   PubMed Web of Science ®Google Scholar
• Spottke AE, Reuter M, Machat O, Cost of illness and its predictors for Parkinson's disease in Germany. PharmacoEconomics 2005;23:817-36
   PubMed Web of Science ®Google Scholar
• Dowding CH, Shenton CL, Salek SS. A review of the health-related quality of life and economic impact of Parkinson's disease. Drugs Aging 2006;23(9):693-721
   PubMed Web of Science ®Google Scholar
• Goetz CG, Tilley BC, Shaftman SR, Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 2008;23(15):2129-70
   PubMed Web of Science ®Google Scholar
• von Campenhausen S, Winter Y, Rodrigues e Silva A, Costs of illness and care in Parkinson's disease: an evaluation in six countries. Eur Neuropsychopharmacol 2011;21(2):180-91
   PubMed Web of Science ®Google Scholar
• Vossius C, Gjerstad M, Baas H, Larsen JP. Drug costs for patients with Parkinson's disease in two different European countries. Acta Neurol Scand 2006;113(4):228-32
   PubMed Web of Science ®Google Scholar
• Ehret R, Balzer-Geldsetzer M, Reese JP, Direkte kosten der parkinson-behandlung: eine erhebung in neurologischen schwerpunktpraxen in Berlin. Nervenarzt 2009;80(4):452-8
   PubMed Web of Science ®Google Scholar
• Reese JP, Winter Y, Balzer-Geldsetzer M, Parkinson's disease: cost-of-illness in an outpatient cohort. Gesundheitswesen 2011;73(1):22-9
   PubMedGoogle Scholar
• Zhao YJ, Tan LC, Li SC, Economic burden of Parkinson's disease in Singapore. Eur J Neurol 2011;18(3):519-26
   PubMed Web of Science ®Google Scholar
• Huse DM, Schulman K, Orsini L, Burden of illness in Parkinson's disease. Mov Disord 2005;20(11):1449-54
   PubMed Web of Science ®Google Scholar
• von Campenhausen S, Winter Y, Gasser J, Cost of illness and health services patterns in Morbus Parkinson in Austria. Wien Klin Wochenschr 2009;121(17-18):574-82
   PubMedGoogle Scholar
• Winter Y, von Campenhausen S, Brozova H, Costs of Parkinson's disease in Eastern Europe: a Czech cohort study. Parkinsonism Relat Disord 2010;16(1):51-6
   PubMed Web of Science ®Google Scholar
• Winter Y, von Campenhausen S, Popov G, Costs of Illness in a Russian cohort of Patients with Parkinson's disease. PharmacoEconomics 2009;27(7):571-84
   PubMed Web of Science ®Google Scholar
• Winter Y, von Campenhausen S, Reese JP, Costs of Parkinson's disease and antiparkinsonian pharmacotherapy: an Italian cohort study. Neurodegener Dis 2011;7(6):365-72
   Google Scholar
• Antonini A, Odin P. Pros and cons of apomorphine and L-dopa continuous infusion in advanced Parkinson's disease. Parkinsonism Relat Disord 2009;15(Suppl 4):S97-100
   PubMedGoogle Scholar
• Factor SA, Feustel PJ, Friedman JH, Longitudinal outcome of Parkinson's disease patients with psychosis. Neurology 2003;60(11):1756-61
   PubMed Web of Science ®Google Scholar
• Aarsland D, Larsen JP, Tandberg E, Laake K. Predictors of nursing home placement in Parkinson's disease: a population-based, prospective study. J Amn Geriat Soc 2000;48(8):938-42
   PubMed Web of Science ®Google Scholar
• Goetz CG, Vogel C, Tanner CM, Stebbins GT. Early dopaminergic drug-induced hallucinations in parkinsonian patients. Neurology 1998;51(3):811-14
   PubMed Web of Science ®Google Scholar
• Happe S, Reese JP, Stiasny-Kolster K, Assessing health-related quality of life in patients with restless legs syndrome. Sleep Med 2009;10(3):295-305
   PubMed Web of Science ®Google Scholar
• Drummond MF, O'Brien BJ, Stoddard GL, Methods for the Economic Evaluation of Health Care Programmes. Oxford University Press; New York: 1997
   Google Scholar
• Gold MR, SJ, Russell LB, Cost-Effectiveness in Health and Medicine. Oxford University Press; New York: 1996
   Google Scholar
• Weinstein MC, SJ, Gold MR, Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 1996;276:1253-8
   PubMed Web of Science ®Google Scholar
• Munneke M, Nijkrake MJ, Keus SH, Efficacy of community-based physiotherapy networks for patients with Parkinson's disease: a cluster-randomised trial. Lancet Neurology 2010;9(1):46-54
   PubMed Web of Science ®Google Scholar
• Brefel-Courbon C, Desboeuf K, Thalamas C, Clinical and economic analysis of spa therapy in Parkinson's disease. Mov Disord 2003;18(5):578-84
   PubMedGoogle Scholar
• Shimbo T, Hira K, Takemura M, Fukui T. Cost-effectiveness analysis of dopamine agonists in the treatment of Parkinson's disease in Japan. PharmacoEconomics 2001;19(8):875-86
   PubMed Web of Science ®Google Scholar
• Hoerger TJ, Bala MV, Rowland C, Cost effectiveness of pramipexole in Parkinson's disease in the US. PharmacoEconomics 1998;14(5):541-57
   PubMed Web of Science ®Google Scholar
• Groenendaal H, Tarrants ML, Armand C. Treatment of advanced Parkinson's disease in the United States: a cost-utility model. Clin Drug Investig 2010;30(11):789-98
   PubMed Web of Science ®Google Scholar
• Hudry J, Rinne JO, Keranen T, Cost-utility model of rasagiline in the treatment of advanced Parkinson's disease in Finland. Ann Pharmacother 2006;40(4):651-7
   PubMed Web of Science ®Google Scholar
• Palmer CS, Nuijten MJ, Schmier JK, Cost effectiveness of treatment of Parkinson's disease with entacapone in the United States. PharmacoEconomics 2002;20(9):617-28
   PubMed Web of Science ®Google Scholar
• Findley LJ, Lees A, Apajasalo M, Cost-effectiveness of levodopa/carbidopa/entacapone (Stalevo) compared to standard care in UK Parkinson's disease patients with wearing-off. Curr Med Res Opin 2005;21(7):1005-14
   PubMed Web of Science ®Google Scholar
• Linna M, Taimela E, Apajasalo M, Marttila RJ. Probabilistic sensitivity analysis for evaluating cost-utility of entacapone for Parkinson's disease. Expert Rev Pharmacoecon Outcomes Res 2002;2(2):91-7
   PubMedGoogle Scholar
• Nuijten MJ, van Iperen P, Palmer C, Cost-effectiveness analysis of entacapone in Parkinson's disease: a Markov process analysis. Value Health 2001;4(4):316-28
   PubMedGoogle Scholar
• Lowin J, Bergman A, Chaudhuri KR, A cost-effectiveness analysis of levodopa/carbidopa intestinal gel compared to standard care in late stage Parkinson's disease in the UK. J Med Econ 2011;14(5):584-93
   PubMedGoogle Scholar
• Kristiansen IS, Bingefors K, Nyholm D, Isacson D. Short-term cost and health consequences of duodenal levodopa infusion in advanced Parkinson's disease in Sweden: an exploratory study. Appl Health Econ Health Policy 2009;7(3):167-80
   PubMedGoogle Scholar
• Spottke EA, Volkmann J, Lorenz D, Evaluation of healthcare utilization and health status of patients with Parkinson's disease treated with deep brain stimulation of the subthalamic nucleus. J Neurol 2002;249(6):759-66
   PubMed Web of Science ®Google Scholar
• Meissner W, Schreiter D, Volkmann J, Deep brain stimulation in late stage Parkinson's disease: a retrospective cost analysis in Germany. J Neurol 2005;252(2):218-23
   PubMed Web of Science ®Google Scholar
• Tomaszewski KJ, Holloway RG. Deep brain stimulation in the treatment of Parkinson's disease: a cost-effectiveness analysis. Neurology 2001;57(4):663-71
   PubMed Web of Science ®Google Scholar
• National Collaborating Centre for Chronic Conditions. Parkinson's Disease: national clinical guideline for diagnosis and management in primary and secondary care. Appendix F. Royal College of Physicians; London: 2006
   Google Scholar
• Valldeoriola F, Morsi O, Tolosa E, Prospective comparative study on cost-effectiveness of subthalamic stimulation and best medical treatment in advanced Parkinson's disease. Mov Disord 2007;22(15):2183-91
   PubMed Web of Science ®Google Scholar
• Willan AR, Goeree R, Pullenayegum EM, Economic evaluation of rivastigmine in patients with Parkinson's disease dementia. PharmacoEconomics 2006;24(1):93-106
   PubMed Web of Science ®Google Scholar
• Clarke CE, Worth P, Grosset D, Stewart D. Systematic review of apomorphine infusion, levodopa infusion and deep brain stimulation in advanced Parkinson's disease. Parkinsonism Relat Disord 2009;15(10):728-41
   PubMed Web of Science ®Google Scholar
• Shearer J, Green C, Counsell CE, Zajicek JP. The use of decision-analytic models in Parkinson's disease: a systematic review and critical appraisal. Appl Health Econ Health Policy 2011;9(4):243-58
   PubMedGoogle Scholar
• Dams J, Bornschein B, Reese JP, Modelling the cost effectiveness of treatments for Parkinson's disease: a methodological review. PharmacoEconomics 2011;29(12):1025-49
   PubMed Web of Science ®Google Scholar
• Siebert U, Bornschein B, Walbert T, Dodel RC. Systematic assessment of decision models in Parkinson's disease. Value Health 2004;7(5):610-26
   PubMedGoogle Scholar
• Nyholm D, Nilsson Remahl AI, Dizdar N, Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology 2005;64(2):216-23
   PubMed Web of Science ®Google Scholar
• Kumar R, Lozano AM, Montgomery E, Lang AE. Pallidotomy and deep brain stimulation of the pallidum and subthalamic nucleus in advanced Parkinson's disease. Mov Disord 1998;13(Suppl 1):73-82
   PubMedGoogle Scholar
• Lang AE, Lozano AM, Montgomery E, Posteroventral medial pallidotomy in advanced Parkinson's disease. NEJM 1997;337(15):1036-42
   PubMed Web of Science ®Google Scholar
• Green AL, Joint C, Sethi H, Cost analysis of unilateral and bilateral pallidotomy for Parkinson's disease. J Clin Neurosci 2004;11(8):829-34
   PubMed Web of Science ®Google Scholar
• Eskandar EN, Flaherty A, Cosgrove GR, Surgery for Parkinson disease in the United States, 1996 to 2000: practice patterns, short-term outcomes, and hospital charges in a nationwide sample. J Neurosurg 2003;99(5):863-71
   PubMed Web of Science ®Google Scholar
• Charles PD, Padaliya BB, Newman WJ, Deep brain stimulation of the subthalamic nucleus reduces antiparkinsonian medication costs. Parkinsonism Relat Disord 2004;10(8):475-9
   PubMedGoogle Scholar
• McIntosh E, Gray A, Aziz T. Estimating the costs of surgical innovations: the case for subthalamic nucleus stimulation in the treatment of advanced Parkinson's disease. Mov Disord 2003;18(9):993-9
   PubMedGoogle Scholar
• Fraix V, Houeto JL, Lagrange C, Clinical and economic results of bilateral subthalamic nucleus stimulation in Parkinson's disease. JNNP 2006;77(4):443-9
   PubMed Web of Science ®Google Scholar
• Mauskopf JA, Paul JE, Grant DM, Stergachis A. The role of cost-consequence analysis in healthcare decision-making. PharmacoEconomics 1998;13(3):277-88
   PubMed Web of Science ®Google Scholar
• Isacson D, Bingefors K, Kristiansen IS, Nyholm D. Fluctuating functions related to quality of life in advanced Parkinson disease: effects of duodenal levodopa infusion. Acta Neurol Scand 2008;118(6):379-86
   PubMed Web of Science ®Google Scholar
• Noyes K, Dick AW, Holloway RG. The implications of using US-specific EQ-5D preference weights for cost-effectiveness evaluation. Med Decis Making 2007;27(3):327-34
   PubMed Web of Science ®Google Scholar
• de la Fuente-Fernandez R, Schulzer M, Mak E, Sossi V. Trials of neuroprotective therapies for Parkinson's disease: problems and limitations. Parkinsonism Relat Disord 2010;16(6):365-9
   PubMed Web of Science ®Google Scholar
• Maetzler W, Liepelt I, Berg D. Progression of Parkinson's disease in the clinical phase: potential markers. Lancet Neurol 2009;8(12):1158-71
   PubMed Web of Science ®Google Scholar
• Willis M, Persson U, Zoellner Y, Gradl B. Reducing uncertainty in value-based pricing using evidence development agreements: the case of continuous intraduodenal infusion of levodopa/carbidopa (Duodopa(R)) in Sweden. Appl Health Econ Health Policy 2011;8(6):377-86
   Google Scholar
• Caro JJ. Pharmacoeconomic analyses using discrete event simulation. PharmacoEconomics 2005;23(4):323-32
   PubMed Web of Science ®Google Scholar
• Caro JJ, Moller J, Getsios D. Discrete event simulation: the preferred technique for health economic evaluations? Value Health 2010;13(8):1056-60
   PubMed Web of Science ®Google Scholar
• Barton P, Bryan S, Robinson S. Modelling in the economic evaluation of health care: selecting the appropriate approach. J Health Serv Res Policy 2004;9(2):110-18
   PubMedGoogle Scholar
• Olanow CW, Rascol O, Hauser R, A double-blind, delayed-start trial of rasagiline in Parkinson's disease. NEJM 2009;361(13):1268-78
   PubMed Web of Science ®Google Scholar
• Wang G, Cheng Q, Zheng R, Economic burden of Parkinson's disease in a developing country: a retrospective cost analysis in Shanghai, China. Mov Disord 2006;21(9):1439-43
   PubMed Web of Science ®Google Scholar
• Keranen T, Kaakkola S, Sotaniemi K. Economic burden and quality of life impairment increase with severity of PD. Parkinsonism Relat Disord 2003;9:163-8
   PubMed Web of Science ®Google Scholar
• Lindgren P, von Campenhausen S, Spottke E, Cost of Parkinson's disease in Europe. Eur J Neurol 2005;12(Suppl 1):68-73
   PubMed Web of Science ®Google Scholar
• Dengler I, Leukel N, Meuser T, Jost WH. Prespektive Erfassung der direkten und indirekten Kosten des idiopathischen Parkinson-Syndroms. Nervenarzt 2006;77(10):1204-9
   PubMedGoogle Scholar
• Dodel RC, Singer M, Kohne-Volland R, The economic impact of Parkinson's disease: an estimation based on a 3-month prospective analysis. PharmacoEconomics 1998;14(3):299-312
   PubMedGoogle Scholar
• Hagell P, Nordling S, Reimer J, Resource use and costs in a Swedish cohort of patients with Parkinson's disease. Mov Disord 2002;17:1213-20
   PubMed Web of Science ®Google Scholar
• Findley L, Aujla M, Bain PG, Direct economic impact of Parkinson's disease: a research survey in the United Kingdom. Mov Disord 2003;18:1139-45
   PubMed Web of Science ®Google Scholar
• McCrone P, Allcock LM, Burn DJ. Predicting the cost of Parkinson's disease. Mov Disord 2007;22(6):804-12
   PubMed Web of Science ®Google Scholar